75.7 F
New York
Monday, August 15, 2022

Date:

Share:

Grünenthal and Averitas Pharma announce initiation of Phase III study with QUTENZA® to prepare label extension in the US for the treatment of post-surgical neuropathic pain

Related Articles

VMRD Begins Manufacturing Key Reagent for Detection of CWD by RT-QuIC

Pullman, WA, August 09, 2022 --(PR.com)-- Veterinary Medical Research & Development (VMRD), Pullman, WA, has partnered with CWD Evolution, Fort Collins, CO, to provide state-of-the-art...

  • Post-surgical neuropathic pain (PSNP) is a debilitating complication of surgery that affects approximately 13 percent of all patients who undergo surgery, which represents 3.3 million patients per year in the US. [1]
  • This Phase III study is Grünenthal’s next step in making QUTENZA available to even more patients in the United States. QUTENZA is the first and only prescription strength capsaicin that is a topical, non-systemic, non-opioid pain treatment; it is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia, and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.

Aachen, Germany, & Morristown, N.J., 30 March 2021 – Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc. will conduct a Phase III trial to study the efficacy, safety and tolerability of QUTENZA (capsaicin) 8% topical…

Read more…

Popular Articles